source
- Celldex halts skin disease program after barzolvolimab fails phase 2 trialCelldex Therapeutics announced it is discontinuing development of its anti‑KIT antibody barzolvolimab for chronic skin disorders after the drug failed to meet its primary endpoint in a phase 2 stud…
- Study finds rising job dissatisfaction and health‑care access uncertainty among U.S. workersA new study shows increasing levels of job dissatisfaction and uncertainty about health‑care access among U.S. workers. The research, funded by AHRQ, surveyed a national sample and found that a gr…